Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice

Cardiovascular Research

Volumn 73, Issue 1, 2007, Pages 227-236

  Gitlin, Jonathan M ^a   Trivedi, Darshini B ^a   Langenbach, Robert ^b   Loftin, Charles D ^a  

^a University of Kentucky   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Abdominal aortic aneurysm; Cardiovascular disease; COX 2; Cyclooxygenase 2; Cyclooxygenase 2 deficient mice; Inflammation

Indexed keywords

ANGIOTENSIN II; CD68 ANTIGEN; CHEMOKINE; CYCLOOXYGENASE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DISEASE SEVERITY; GENE EXPRESSION; GENETIC DISORDER; INCIDENCE; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; WILD TYPE;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CYCLOOXYGENASE 2; IMMUNOHISTOCHEMISTRY; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, ANIMAL; RNA, MESSENGER; TIME FACTORS;

EID: 33845592174     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.10.015     Document Type: Article

References (41)

1. Wassef M., Baxter B.T., Chisholm R.L., Dalman R.L., Fillinger M.F., Heinecke J., et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 34 (2001) 730-738
2. Thompson R.W., Holmes D.R., Mertens R.A., Liao S., Botney M.D., Mecham R.P., et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96 (1995) 318-326
3. Hance K.A., Tataria M., Ziporin S.J., Lee J.K., and Thompson R.W. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 35 (2002) 254-261
4. Curci J.A., Liao S., Huffman M.D., Shapiro S.D., and Thompson R.W. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 102 (1998) 1900-1910
5. Walton L.J., Franklin I.J., Bayston T., Brown L.C., Greenhalgh R.M., Taylor G.W., et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 100 (1999) 48-54
6. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
7. Holmes D.R., Wester W., Thompson R.W., and Reilly J.M. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 25 (1997) 810-815
8. Miralles M., Wester W., Sicard G.A., Thompson R., and Reilly J.M. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 29 (1999) 884-892
9. Holmes D.R., Petrinec D., Wester W., Thompson R.W., and Reilly J.M. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 63 (1996) 305-309
10. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 (2000) 1605-1612
11. Deng G.G., Martin-McNulty B., Sukovich D.A., Freay A., Halks-Miller M., Thinnes T., et al. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res 92 (2003) 510-517
12. Saraff K., Babamusta F., Cassis L.A., and Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23 (2003) 1621-1626
13. Ishibashi M., Egashira K., Zhao Q., Hiasa K., Ohtani K., Ihara Y., et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 24 (2004) e174-e178
14. King V.L., Trivedi D.B., Gitlin J.M., and Loftin C.D. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1137-1143
15. Yang H.M., Kim H.S., Park K.W., You H.J., Jeon S.I., Youn SW., et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110 (2004) 301-308
16. Armstrong P.J., Franklin D.P., Carey D.J., and Elmore J.R. Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg 19 (2005) 248-257
17. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
18. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (2002) [RESEARCH0034]
19. Gilsbach R., Kouta M., Bonisch H., and Bruss M. Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 40 (2006) 173-177
20. Kudo I., and Murakami M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 38 (2005) 633-638
21. Daugherty A., and Cassis L.A. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 24 (2004) 429-434
22. Derbyshire Z.E., Halfter U.M., Heimark R.L., Sy T.H., and Vaillancourt R.R. Angiotensin II stimulated transcription of cyclooxygenase II is regulated by a novel kinase cascade involving Pyk2, MEKK4 and annexin II. Mol Cell Biochem 271 (2005) 77-90
23. Young W., Mahboubi K., Haider A., Li I., and Ferreri N.R. Cyclooxygenase-2 is required for tumor necrosis factor-alpha-and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 86 (2000) 906-914
24. Burleigh M.E., Babaev V.R., Yancey P.G., Major A.S., McCaleb J.L., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39 (2005) 443-452
25. Tham D.M., Martin-McNulty B., Wang Y.X., Wilson D.W., Vergona R., Sullivan M.E., et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11 (2002) 21-30
26. Ayabe N., Babaev V.R., Tang Y., Tanizawa T., Fogo A.B., Linton M.F., et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis 184 (2006) 312-321
27. Zhao L., Moos M.P., Grabner R., Pedrono F., Fan J., Kaiser B., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
28. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 111 (2005) 816-828
29. Erbel R., and Eggebrecht H. Aortic dimensions and the risk of dissection. Heart 92 (2006) 137-142
30. Brady A.R., Thompson S.G., Fowkes F.G., Greenhalgh R.M., and Powell J.T. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110 (2004) 16-21
31. Daugherty A., and Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann NY Acad Sci 892 (1999) 108-118
32. Norwood V.F., Morham S.G., and Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 58 (2000) 2291-2300
33. Qi Z., Hao C.M., Langenbach R.I., Breyer R.M., Redha R., Morrow J.D., et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 110 (2002) 61-69
34. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11 (2005) 1330-1338
35. Li F., Zhang C., Schaefer S., Estes A., and Malik K.U. ANG II-induced neointimal growth is mediated via cPLA2-and PLD2-activated Akt in balloon-injured rat carotid artery. Am J Physiol Heart Circ Physiol 289 (2005) H2592-H2601
36. Steffel J., Hermann M., Greutert H., Gay S., Luscher T.F., Ruschitzka F., et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111 (2005) 1685-1689
37. Salmon J.A., Smith D.R., Flower R.J., Moncada S., and Vane J.R. Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta 523 (1978) 250-262
38. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
39. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 351 (2004) 1707-1709
40. Narumiya S., and FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108 (2001) 25-30
41. Bayston T., Ramessur S., Reise J., Jones K.G., and Powell J.T. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 38 (2003) 354-359